{"disease":{"id":"her2-positive-biliary-tract-cancer","name":"her2 positive biliary tract cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04450732","title":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT05985707","title":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT05749900","title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04722133","title":"Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04578444","title":"An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}